A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin

Nature Structural and Molecular Biology

Volumn 20, Issue 3, 2013, Pages 363-370

  Xu, Rui ^a   Krause, Jens C ^b   Mcbride, Ryan ^a   Paulson, James C ^a   Crowe Jr , James E ^b,c   Wilson, Ian A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; INFLUENZA VIRUS A H2N2; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGEN-ANTIBODY COMPLEX; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; EPITOPES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLUENZA A VIRUS, H2N2 SUBTYPE; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION; TRYPTOPHAN; TYROSINE;

ORTHOMYXOVIRIDAE;

EID: 84875186505     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.2500     Document Type: Article

References (45)

1. Gilbert, S.C. Advances in the development of universal influenza vaccines. Influenza Other Respi. Viruses published online, doi:10.1111/irv.12013 (24 September 2012).
2. Ekiert, D.C. & Wilson, I.A. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr. Opin. Virol. 2, 134-141 (2012).
3. Du, J., Cross, T.A. & Zhou, H.X. Recent progress in structure-based anti-influenza drug design. Drug Discov. Today 17, 1111-1120 (2012).
4. Skehel, J.J. & Wiley, D. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
5. Paulson, J.C. Interactions of animal viruses with cell surface receptors. in The Receptors Vol. 2, 131-219 (Academic Press, 1985).
6. Weis, W. et al. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333, 426-431 (1988).
7. Matrosovich, M. & Klenk, H.D. Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding. Rev. Med. Virol. 13, 85-97 (2003).
8. Sauter, N.K. et al. Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study. Biochemistry 28, 8388-8396 (1989).
9. Vigerust, D.J. & Shepherd, V.L. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 15, 211-218 (2007).
10. Sagar, M., Wu, X., Lee, S. & Overbaugh, J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80, 9586-9598 (2006).
11. Wilson, I.A. & Cox, N.J. Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. 8, 737-771 (1990).
12. Whittle, J.R. et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. USA 108, 14216-14221 (2011).
13. Ekiert, D.C. et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526-532 (2012).
14. Lee, P.S. et al. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc. Natl. Acad. Sci. USA 109, 17040-17045 (2012).
15. Ohshima, N. et al. Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. J. Virol. 85, 11048-11057 (2011).
16. Krause, J.C. et al. Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J. Virol. 86, 6334-6340 (2012).
17. Yoshida, R. et al. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 5, e1000350 (2009).
18. Serfling, R.E., Sherman, I.L. & Houseworth, W.J. Excess pneumonia-influenza mortality by age and sex in three major influenza A2 epidemics, United States, 1957-58, 1960 and 1963. Am. J. Epidemiol. 86, 433-441 (1967).
19. Housworth, J. & Langmuir, A.D. Excess mortality from epidemic influenza, 1957-1966. Am. J. Epidemiol. 100, 40-48 (1974).
20. Simonsen, L. et al. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J. Infect. Dis. 178, 53-60 (1998).
21. Nabel, G.J., Wei, C.J. & Ledgerwood, J.E. Vaccinate for the next H2N2 pandemic now. Nature 471, 157-158 (2011).
22. Schäfer, J.R. et al. Origin of the pandemic 1957 H2 influenza A virus and the persistence of its possible progenitors in the avian reservoir. Virology 194, 781-788 (1993).
23. Ma, W. et al. Identification of H2N3 influenza A viruses from swine in the United States. Proc. Natl. Acad. Sci. USA 104, 20949-20954 (2007).
24. Kaverin, N.V. et al. Cross-protection and reassortment studies with avian H2 influenza viruses. Arch. Virol. 145, 1059-1066 (2000).
25. Huang, C.C. et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. USA 101, 2706-2711 (2004).
26. Chan, C.H., Hadlock, K.G., Foung, S.K. & Levy, S.V. (H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97, 1023-1026 (2001).
27. Marasca, R. et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am. J. Pathol. 159, 253-261 (2001).
28. Carbonari, M. et al. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J. Immunol. 174, 6532-6539 (2005).
29. Zhou, T. et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732-737 (2007).
30. Luftig, M.A. et al. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat. Struct. Mol. Biol. 13, 740-747 (2006).
31. Ekiert, D.C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251 (2009).
32. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273 (2009).
33. Kashyap, A.K. et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. 105, 5986-5991 (2008).
34. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (2007).
35. Xu, R., McBride, R., Paulson, J.C., Basler, C.F. & Wilson, I.A. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J. Virol. 84, 1715-1721 (2010).
36. Okuno, Y., Isegawa, Y., Sasao, F. & Ueda, S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67, 2552-2558 (1993).
37. Yamada, A., Brown, L.E. & Webster, R.G. Characterization of H2 influenza virus hemagglutinin with monoclonal antibodies: influence of receptor specificity. Virology 138, 276-286 (1984).
38. Krause, J.C. et al. Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J. Immunol. 187, 3704-3711 (2011).
39. Liu, J. et al. Structures of receptor complexes formed by hemagglutinins from the Asian Influenza pandemic of 1957. Proc. Natl. Acad. Sci. USA 106, 17175-17180 (2009).
40. Xu, R. et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328, 357-360 (2010).
41. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
42. McCoy, A.J., Grosse-Kunstleve, R.W., Storoni, L.C. & Read, R.J. Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61, 458-464 (2005).
43. Adams, P.D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58, 1948-1954 (2002).
44. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
45. Xu, R., McBride, R., Nycholat, C.M., Paulson, J.C. & Wilson, I.A. Structural characterization of the hemagglutinin receptor specificity from the 2009 H1N1 influenza pandemic. J. Virol. 86, 982-990 (2012).